title: Risk of cerebral angiography in patients with symptomatic intracranial atherosclerotic stenosis.
abstract: BACKGROUND
  A well-defined rate of adverse events following cerebral angiography in patients with symptomatic intracranial atherosclerosis would be useful to physicians making decisions regarding imaging and treatment of these patients. We report the adverse events associated with angiography in patients who underwent single-vessel cerebral angiography as part of the study protocol in the Warfarin-Aspirin for Symptomatic Intracranial Arterial Stenosis trial.
  
  
  METHODS
  Single-vessel cerebral angiography was performed to specifically define the degree of stenosis in 196 patients suspected of having intracranial atherosclerotic stenosis on noninvasive tests. Adverse events that occurred within 24 h of cerebral angiography were reported by the sites performing the angiography.
  
  
  RESULTS
  Overall, neurological adverse events occurred in 4 patients (2.0%; 95% CI: 0.6-5.1%), and nonneurological adverse events occurred in 12 patients (6.1%; 95% CI: 3.2-10.5%). All of the neurological adverse events were transient.
  
  
  CONCLUSIONS
  The risk of permanent neurological adverse events associated with single-vessel cerebral angiography in patients with symptomatic intracranial atherosclerosis is relatively low. The quantification of the risk of cerebral angiography in patients with intracranial atherosclerosis provides useful information to consider when evaluating noninvasive imaging techniques for their relative value.
authors.affiliation: Departments of Radiology and Neurosurgery, Mayo Clinic, Rochester, MN 55901, USA. cloft.harry@mayo.edu
authors.forename: Harry J
authors.initials: HJ
authors.lastname: Cloft
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Lynn
authors.forename: Edward
authors.initials: E
authors.lastname: Feldmann
authors.forename: Marc
authors.initials: M
authors.lastname: Chimowitz
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002533:Cerebral Angiography / Q000009:adverse effects* / Q000706:statistics & numerical data*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000453:epidemiology*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012307:Risk Factors; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin; D001241:Aspirin